GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational ...

These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss drugs, known as GLP-1 agonists, might transform societies and save countries ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

The use of GLP-1-agonists was associated with a significantly reduced risk of hospitalisation due to alcohol use disorder. Semaglutide was associated with a 36% lower risk, and liraglutide with a ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community needs to figure out how to keep patients on the drugs long term to fully ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and ...

The company reported its dual GLP-1/GIP co-agonist drug VK2735 saw up to an average of 8.2% weight loss over 28 days on its highest-tested dose of 100 mg. Sources: AstraZeneca , ObesityWeek ...

Fractyl Health Inc. has nominated RJVA-002, a GIP/GLP-1 dual agonist, as its first pancreatic gene therapy candidate for obesity. BioWorld Science Endocrine/metabolic Gene therapy Popular Stories ...